A Validated Chiral Chromatography Method for Enantiomeric Separation of Pomalidomide in Human Plasma.
J Chromatogr Sci
; 62(7): 611-617, 2024 Aug 20.
Article
en En
| MEDLINE
| ID: mdl-38745428
ABSTRACT
In the present work, new chiral stationary phase high-performance liquid chromatography (CSP-HPLC) method was established and validated for the quantification of pomalidomide (PMD) enantiomers in human plasma. The chromatographic enantiomeric separation was achieved on a Daicel-CSP, Chiralpack IA 4.6 × 250 mm, 5 µm; because of its advantages of high degree of retention, high resolution capacity, better reproducibility, ability to produce lower back pressure and low degree of tailing. The mobile phase was maintained as methanol glacial acetic acid (499.50 ml50 µL). Ultraviolet wavelength for detection was 220 nm. PMD enantiomer-I and enantiomer-II were separated at 8.83 and 15.34 min, respectively. Limit of detection and limit of quantification for each enantiomer and the calibration curve of standard PMD was linear in range between 10-5,000 ng mL-1. The method was validated according to The International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH(Q2R1)) specific guidelines. We found no interference peak with PMD chromatogram obtained. This is a simple, reliable and specific method for detection and quantification of enantiomer of PMD in human plasma sample.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Talidomida
/
Límite de Detección
Límite:
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article